UK institute confirms narrow guidance for infliximab in colitis
This article was originally published in Scrip
Executive Summary
Schering-Plough's Remicade (infliximab, licensed from Johnson & Johnson) has been recommended for treating exacerbations of severely active ulcerative colitis in the national health service in England and Wales, but only in patients in whom ciclosporin is contraindicated. The National Institute for health and Clinical Exellencehas published guidance confirming its draft recommendations on the product in this indication (Scrip Online, August 13th, 2008). Local health authorities normally have three months to implement NICE guidance in clinical practice after it has been published.